1.28

6.57% -0.09

Pre-market: 1.30 0.02 +1.56%

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $1.28, with a volume of 751.30K. It is down -6.57% in the last 24 hours and up +0.79% over the past month. Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Previous Close:

$1.37

Open:

$1.39

24h Volume:

751.30K

Relative Volume:

1.73

Market Cap:

$54.06M

Revenue:

$88.55M

Net Income/Loss:

$-53.21M

P/E Ratio:

-0.9893

EPS:

-1.2939

Net Cash Flow:

$-29.48M

1W Performance:

-14.09%

1M Performance:

+0.79%

6M Performance:

-49.80%

1Y Performance:

-57.76%

1-Day Range:

$1.22

$1.39

1-Week Range:

$1.22

$1.565

52-Week Range:

$1.13

$3.88

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1104)

Industry

Medical Devices (141)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

296

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	1.28	54.06M	88.55M	-53.21M	-29.48M	-1.2939
ABT Abbott Laboratories	88.67	154.45B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	307.94	118.05B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	80.38	103.20B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	46.76	69.50B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.28	49.68B	6.30B	1.07B	1.09B	1.8406

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-25	Downgrade	Piper Sandler	Overweight → Neutral
Mar-10-25	Initiated	D. Boral Capital	Buy
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

Jun 09, 2026

LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 09, 2026

Pulmonx (LUNG) awards 40,000 restricted stock units to director - Stock Titan

Jun 09, 2026

Director Ferrari (LUNG) awarded 40,000 Pulmonx restricted stock units - Stock Titan

Jun 09, 2026